DK4076652T3 - Farmaceutisk acceptabelt atrasentansalt til anvendelse i en fremgangsmåde til behandling af iga-nefropati - Google Patents

Farmaceutisk acceptabelt atrasentansalt til anvendelse i en fremgangsmåde til behandling af iga-nefropati

Info

Publication number
DK4076652T3
DK4076652T3 DK20903533.6T DK20903533T DK4076652T3 DK 4076652 T3 DK4076652 T3 DK 4076652T3 DK 20903533 T DK20903533 T DK 20903533T DK 4076652 T3 DK4076652 T3 DK 4076652T3
Authority
DK
Denmark
Prior art keywords
atrasentan
salt
pharmaceutically acceptable
iga nephropathy
treating iga
Prior art date
Application number
DK20903533.6T
Other languages
English (en)
Inventor
Philip Thomas Frohlich
Andrew James King
Chidambaram Ramachandran
Sarah Beth Noonberg
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Application granted granted Critical
Publication of DK4076652T3 publication Critical patent/DK4076652T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DK20903533.6T 2019-12-17 2020-12-16 Farmaceutisk acceptabelt atrasentansalt til anvendelse i en fremgangsmåde til behandling af iga-nefropati DK4076652T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US202063125205P 2020-12-14 2020-12-14
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Publications (1)

Publication Number Publication Date
DK4076652T3 true DK4076652T3 (da) 2026-03-02

Family

ID=76478538

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20903533.6T DK4076652T3 (da) 2019-12-17 2020-12-16 Farmaceutisk acceptabelt atrasentansalt til anvendelse i en fremgangsmåde til behandling af iga-nefropati

Country Status (21)

Country Link
US (11) US20210353593A1 (da)
EP (2) EP4076652B1 (da)
JP (2) JP7624995B2 (da)
KR (1) KR20230015874A (da)
CN (3) CN116327758A (da)
AU (1) AU2020404984A1 (da)
BR (1) BR112022012075A2 (da)
CA (1) CA3161516A1 (da)
DK (1) DK4076652T3 (da)
FI (1) FI4076652T3 (da)
HR (1) HRP20260121T1 (da)
IL (1) IL293921A (da)
LT (1) LT4076652T (da)
MX (1) MX2022007471A (da)
PH (1) PH12022551456A1 (da)
PL (1) PL4076652T3 (da)
PT (1) PT4076652T (da)
RS (1) RS67746B1 (da)
SI (1) SI4076652T1 (da)
TW (2) TWI914232B (da)
WO (1) WO2021126977A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
US20250352511A1 (en) * 2022-05-19 2025-11-20 Chinook Therapeutics, Inc. Methods of treating focal segmental glomerulosclerosis with atrasentan
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
JP2025533903A (ja) * 2022-10-05 2025-10-09 デーウン ファーマシューティカル カンパニー リミテッド エナボグリフロジンを含む腎障害及び／又は糖尿病の予防又は治療用薬学組成物｛ｐｈａｒｍａｃｅｕｔｉｃａｌ ｃｏｍｐｏｓｉｔｉｏｎ ｆｏｒ ｐｒｅｖｅｎｔｉｏｎ ｏｒ ｔｒｅａｔｍｅｎｔ ｏｆ ｎｅｐｈｒｏｐａｔｈｙ ａｎｄ／ｏｒ ｄｉａｂｅｔｅｓ ｍｅｌｌｉｔｕｓ， ｃｏｍｐｒｉｓｉｎｇ ｅｎａｖｏｇｌｉｆｌｏｚｉｎ｝
EP4608396A1 (en) * 2022-10-28 2025-09-03 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
KR20250090355A (ko) 2022-11-07 2025-06-19 산레노 테라퓨틱스 (상하이) 리미티드 Iga 신병증 치료를 위한 엔도텔린 수용체 길항제 및 글루코코르티코이드의 조합
WO2025261457A1 (zh) * 2024-06-21 2025-12-26 深圳信立泰药业股份有限公司 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
CA2479254A1 (en) 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for renal disease
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
EP1766396B1 (en) 2004-06-07 2010-08-11 Ramot at Tel-Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
US20060189675A1 (en) 2004-09-17 2006-08-24 Steve King Crystalline form of a drug
US20060135596A1 (en) 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
JP2008513481A (ja) 2004-09-17 2008-05-01 アボット・ラボラトリーズ アトラセンタン塩酸塩の結晶形２
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
EP2015768A1 (en) * 2006-03-27 2009-01-21 Genentech, Inc. Methods for treating kidney disorders
US20100022568A1 (en) 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CN101970685B (zh) 2007-01-16 2013-08-07 Musc研究发展基金会 诊断前列腺疾病的试剂盒
JP2010535210A (ja) 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
DK3222277T3 (da) 2009-03-31 2020-05-11 Ligand Pharm Inc Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati
EP2509594A1 (en) 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
US9365445B2 (en) 2010-07-28 2016-06-14 Nippon Electric Glass Co., Ltd. Method for producing phosphor-encapsulating capillary tube, phosphor-encapsulating capillary tube, wavelength-converting member, and method for producing wavelength-converting member
WO2014138738A1 (en) * 2013-03-08 2014-09-12 Abbive Inc. Methods of treating acute kidney injury
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
KR20160029125A (ko) 2013-07-08 2016-03-14 애브비 인코포레이티드 아트라센탄을 포함하는 안정화된 약제학적 용량형
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN107106522A (zh) * 2014-11-07 2017-08-29 艾伯维公司 使用液体潴留的预测因子治疗ckd的方法
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
WO2017011772A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of multidrug-resistant nephrotic syndrome (mdr-ns) in children
CA3132021C (en) * 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
SG11201805695SA (en) 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
MA46524A (fr) 2016-10-13 2019-08-21 Retrophin Inc Composés de biphényl-sulfonamide destinés au traitement de néphropathies
EP4134080B1 (en) 2016-11-23 2024-11-13 ChemoCentryx, Inc. Ccr2 inhibitors for use in treating renal diseases
US10758540B2 (en) 2017-10-11 2020-09-01 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
MY210547A (en) 2017-11-30 2025-09-30 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
US20230270718A1 (en) 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Also Published As

Publication number Publication date
US11491137B2 (en) 2022-11-08
TW202130350A (zh) 2021-08-16
LT4076652T (lt) 2026-02-25
EP4076652A1 (en) 2022-10-26
US20230355580A1 (en) 2023-11-09
US20230129646A1 (en) 2023-04-27
US12370174B2 (en) 2025-07-29
PT4076652T (pt) 2026-02-12
US20220288026A1 (en) 2022-09-15
TWI914232B (zh) 2026-02-01
US11998526B2 (en) 2024-06-04
US20210353593A1 (en) 2021-11-18
WO2021126977A1 (en) 2021-06-24
US20240108599A1 (en) 2024-04-04
FI4076652T3 (fi) 2026-02-10
CN116327758A (zh) 2023-06-27
US12521369B2 (en) 2026-01-13
JP7821870B2 (ja) 2026-02-27
JP2023507739A (ja) 2023-02-27
SI4076652T1 (sl) 2026-03-31
HRP20260121T1 (hr) 2026-03-13
AU2020404984A1 (en) 2022-07-14
US20230355579A1 (en) 2023-11-09
TWI875895B (zh) 2025-03-11
US20250281454A1 (en) 2025-09-11
CN113272013A (zh) 2021-08-17
US20230364055A1 (en) 2023-11-16
US12582631B2 (en) 2026-03-24
EP4710928A3 (en) 2026-04-15
PH12022551456A1 (en) 2023-10-23
EP4076652B1 (en) 2025-12-03
JP2025060686A (ja) 2025-04-10
EP4076652A4 (en) 2024-01-03
WO2021126977A9 (en) 2021-07-22
BR112022012075A2 (pt) 2022-08-30
RS67746B1 (sr) 2026-03-31
TW202545517A (zh) 2025-12-01
US20220288027A1 (en) 2022-09-15
CN116173014A (zh) 2023-05-30
US20220304978A1 (en) 2022-09-29
JP7624995B2 (ja) 2025-01-31
US20250120945A1 (en) 2025-04-17
KR20230015874A (ko) 2023-01-31
PL4076652T3 (pl) 2026-03-23
US12121509B2 (en) 2024-10-22
EP4710928A2 (en) 2026-03-18
IL293921A (en) 2022-08-01
CA3161516A1 (en) 2021-06-24
MX2022007471A (es) 2022-08-17

Similar Documents

Publication Publication Date Title
HRP20260121T1 (hr) Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
FIC20260007I1 (fi) Vimseltinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
IL282794A (en) Therapeutic methods
DK3998261T3 (da) Pyrimidin-2-ylamino-1h-pyrazoler som lrrk2-inhibitorer til brug i behandlingen af neurodegenerative lidelser
IL289192A (en) Method for treating idiopathic pulmonary fibrosis
DE112016003746A5 (de) Steller zum Verstellen eines Verstellorgans
DK3244933T3 (da) Apparat, fremgangsmåde og softwareprodukt til hånddesinfektion ved anvendelse af ozonholdigt vand
DK3429571T3 (da) Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme
DK4434585T3 (da) Forbindelser og fremgangsmåder til reduktion af snca-ekspression
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3237578T3 (da) Fremgangsmåde og anordning til reduktion af tunge aromatiske polycikliske forbindelser i hydrokrakningsenheder
DK3119660T3 (da) System og fremgangsmåde til positionering af en arbejdsmaskine
PL4034682T3 (pl) Sposób redukcji bezpośredniej wykorzystujący wodór
DK3215689T3 (da) Løftemekanisme til at løfte konstruktionsplader, løfteapparatur omfattende denne mekanisme og løftefremgangsmåden under anvendelse af dette apparatur
IL286040A (en) Methods of treating al amyloidosis
EP3856052C0 (en) Orthopedic Cement Removal Tools
DK3773589T3 (da) RET-inhibitor til anvendelse i behandling af cancer med en RET-ændring
DK3250830T3 (da) Indretning til styring af strømningen i en strømningsmaskine, strømningsmaskine og fremgangsmåde
DK4034122T3 (da) Fremgangsmåder til behandling af hyperfenylalaninæmi
IL287130A (en) Methods of treating pruritus
DK3952858T3 (da) Fremgangsmåde til behandling af tumorer
DK3340993T3 (da) Forbindelse til anvendelse i fremgangsmåder til behandling af polycystisk nyresygdom
DK3930715T3 (da) Saracatinib til anvendelse til behandling af idiopatisk lungefibrose
DK3976791T3 (da) Forbindelser og fremgangsmåder til at reducere fus-ekspression
DK3359170T3 (da) Fremgangsmåder til behandling af nuklear faktor kappa-letkæde-enhancer af aktiveret b-celle-(nf-kb)-dysregulering hos en vært med behov derfor ved hjælp af æggeskalsmembransammensætninger